I read with great interest, the manuscript by Hung et al, 1 recently published in your esteemed journal. As abdominal paracentesis (AP) is considered a relatively safe procedure and done very commonly in evaluating a patient of cirrhosis with ascites, it becomes extremely crucial to carefully select the subset of patients at higher risk of developing post-paracentesis hemoperitoneum (PPH). Points which need additional emphasis from the current study include: Firstly, operator-related factors have not been considered in the present study. In a systematic review by Sharzehi et al, 2 it was shown that majority of haemorrhagic complications after paracentesis were noted when non-trainee physicians performed AP. Secondly, procedure-related factors including gauge of the needle used and ultrasound (USG) guidance for AP have to be looked into. The American Association for the Study of Liver Diseases recommends using 15 or 16 gauge needle for therapeutic paracentesis. 3 It would be worthwhile to note any difference in PPH based on the gauge of needle used for AP especially in the high risk group of patients. Using USG guidance for AP can prevent injuring any abdominal wall collaterals and would thus theoretically reduce the risk of PPH. It would be interesting to document any decrease in the risk of PPH using this modality in future studies conducted on high risk groups. Thirdly, as the conventional coagulation parameters like the international normalized ratio and platelet count are poor measures to ascertain the extent of underlying bleeding abnormality in patients with cirrhosis, future studies should aim to use more reliable investigations like thromboelastography (TEG) especially in patients at high risk for developing PPH.Fourthly, the severity of liver disease, based on Model for endstage liver disease (MELD) score did not impact the occurrence of PPH in the current study. However in a study done by Pache et al,4 the authors noted high MELD score and renal dysfunction as significant predictors to develop haemorrhagic complications after AP.Based on the current data, it is imperative that we carefully delineate the subset of patients who are at high risk of developing PPH after AP (those with severe liver disease having a high MELD score with associated renal dysfunction) and institute cautious measures like performing AP under USG guidance by an experienced physician using a relatively higher gauge needle and utilizing strategies like TEGguided blood product transfusions prior to performing AP.